• **Name:** Sun Min Lim
• **Current Position & Affiliation:** Associate Professor
Yonsei University College of Medicine
• **Country:** Korea

• **Educational Background:**

2010.9 ~ 2017.2	Doctor of Philosophy, Yonsei University Graduate School
2002.3 ~ 2008.2	College of Medicine, Yonsei University, Seoul, Republic of Korea
2006.1 ~ 2006.2	Washington University School of Medicine, St Louis, Missouri (Visiting student)

• **Professional Experience:**

2008.3 ~ 2009.2	Internship, Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
2009.3 ~ 2013.2	Residency in Internal Medicine. Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea
2012.3~ 2013.2	Chief medical resident, Department of Internal medicine, Severance Hospital
2013.3~ 2015.8	Fellow, Division of Medical Oncology, Department of Internal Medicine, Severance Hospital
2015.9~ 2020.2	Assistant Professor, CHA Bundang Medical Center, CHA University
2020.3~ 2023.2	Assistant Professor, Severance Hospital, Yonsei University Health System
2023.3~ current	Associate Professor, Severance Hospital, Yonsei University Health System

• **Professional Organizations:**

2012~ ongoing	Member, American Society of Clinical Oncology
2012~ ongoing	Member, American Association of Cancer Research
2012~ ongoing	Member, Korean Association for Clinical Oncology
2012~ ongoing	Member, Korean Cancer Study Group
2013~ ongoing	Member, International Association for the Study of Lung Cancer

• **Main Scientific Publications:**

1. Jing Zhang*, Lim SM*, et al. D3S-001, a KRAS G12C inhibitor with rapid target

engagement kinetics, overcomes nucleotide cycling, and demonstrates robust preclinical and clinical activities. Cancer Discovery 2024; (9): 1675-1698.

2. Lim SM*, Peters S*, et al. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. Nat Commun 2023; 14(1): 7301
3. Oh SY, Lim SM* and Yun MR*. Preclinical study of a biparatopic METxMET antibody-drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res 2023; 29: 221-32.